\-\ Texto\\:\\ \ \(0\)\
\-\ abd\\:\\ midepigastric\\ tenderness\\.\ \(0\)\
\-\ labs\\:\\ hyperbilirubinemia\\.\\ mildly\\ elevated\\ lfts\\.\\ elevated\\ amylase\\ and\\ lipase\\.\ \(0\)\
\-\ therapy\\ for\\ underlying\\ metastatic\\ pancreatic\\ carcinoma\\.\ \(0\)\
\-\ ct\\:\\ cavernous\\ transformation\\ of\\ the\\ thrombosed\\ portal\\ vein\\ occurs\\ when\\ small\\ collateral\\ veins\\ adjacent\\ to\\ the\\ portal\\ vein\\ expand\\ and\\ replace\\ the\\ obliterated\\ portal\\ vein\\.\\ in\\ this\\ case\\,\\ pv\\ thrombosis\\ is\\ secondary\\ to\\ a\\ pancreatic\\ primary\\ neoplasm\\ with\\ evidence\\ of\\ metastatic\\ spread\\.\\ the\\ pv\\ thrombus\\ may\\ be\\ secondary\\ to\\ direct\\ tumor\\ extension\\ or\\ may\\ be\\ the\\ sequelae\\ of\\ a\\ paraneoplastic\\ syndrome\\ \\(hypercoagulable\\ state\\)\\.\\ peripheral\\ hypodense\\ liver\\ lesions\\ are\\ likely\\ metastases\\.\ \(0\)\
\-\ portal\\ vein\\ thrombosis\\ with\\ cavernous\\ transformation\\ in\\ metastatic\\ pancreatic\\ cancer\ \(0\)\
\-\ 1\\.\\ \\ tumor\\:\\ direct\\ invasion\\ of\\ the\\ pv\\,\\ pv\\ compression\\ or\\ paraneoplastic\\ hypercoagulability\\ \ \(0\)\
\-\ 2\\.\\ \\ cirrhosis\ \(0\)\
\-\ 3\\.\\ \\ infection\\ \\(esp\\.\\ in\\ children\\)\ \(0\)\
\-\ 4\\.\\ \\ inflammation\\ \\(pancreatitis\\)\ \(0\)\
\-\ 5\\.\\ \\ inherited\\ coagulation\\ disorders\ \(0\)\
\-\ 6\\.\\ \\ idiopathic\ \(0\)\
\-\ 51\\ year\\ old\\ asian\\ woman\\ with\\ right\\ upper\\ quadrant\\ abdominal\\ pain\\,\\ nausea\\.\\ 20\\ lb\\ weightloss\\.\ \(0\)\
\-\ portal\\ vein\\ obstruction\\ does\\ not\\ affect\\ liver\\ function\\ unless\\ the\\ patient\\ has\\ an\\ underlying\\ liver\\ disease\\ such\\ as\\ cirrhosis\\.\\ this\\ is\\ partially\\ due\\ to\\ a\\ rapid\\ arterial\\ buffer\\ response\\,\\ with\\ compensatory\\ increased\\ flow\\ of\\ the\\ hepatic\\ artery\\ maintaining\\ the\\ total\\ hepatic\\ blood\\ flow\\.\\ formation\\ of\\ collaterals\\ occurs\\ rather\\ rapidly\\ as\\ well\\,\\ and\\ they\\ have\\ been\\ described\\ as\\ early\\ as\\ 12\\ days\\ after\\ acute\\ thrombosis\\,\\ though\\ the\\ average\\ time\\ to\\ formation\\ is\\ approximately\\ 5\\ weeks\\.\\ \ \(0\)\
\-\ the\\ development\\ of\\ a\\ collateral\\ circulation\\,\\ with\\ its\\ attendant\\ risk\\ of\\ variceal\\ hemorrhage\\,\\ is\\ responsible\\ for\\ most\\ of\\ the\\ complications\\ and\\ is\\ the\\ most\\ common\\ manifestation\\ of\\ portal\\ vein\\ obstruction\\.\\ other\\ sequelae\\ of\\ the\\ subsequent\\ portal\\ hypertension\\,\\ such\\ as\\ ascites\\,\\ are\\ less\\ frequent\\.\\ rarely\\,\\ the\\ thrombosis\\ extends\\ from\\ the\\ portal\\ vein\\ to\\ the\\ mesenteric\\ arcades\\,\\ leading\\ to\\ bowel\\ ischemia\\ and\\ infarction\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ portal\\:\\ 0\\.42412043250478\ \(0\)\
\-\ pv\\:\\ 0\\.3386251498248133\ \(0\)\
\-\ vein\\:\\ 0\\.27796197581433707\ \(0\)\
\-\ the\\:\\ 0\\.1879175618556118\ \(0\)\
\-\ thrombosis\\:\\ 0\\.18066942433829833\ \(0\)\
\-\ pancreatic\\:\\ 0\\.15066362822499793\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.13679869546710033\ \(0\)\
\-\ of\\:\\ 0\\.11925328829657522\ \(0\)\
\-\ sequelae\\:\\ 0\\.11759675748256758\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.11671373540389036\ \(0\)\
\-\ liver\\:\\ 0\\.11464898608634119\ \(0\)\
\-\ transformation\\:\\ 0\\.1131724781920245\ \(0\)\
\-\ as\\:\\ 0\\.11127737686351483\ \(0\)\
\-\ collateral\\:\\ 0\\.106030108126195\ \(0\)\
\-\ direct\\:\\ 0\\.09766295102647236\ \(0\)\
\-\ to\\:\\ 0\\.09694631622001351\ \(0\)\
\-\ cavernous\\:\\ 0\\.09610827027017257\ \(0\)\
\-\ metastatic\\:\\ 0\\.09114963866968621\ \(0\)\
\-\ underlying\\:\\ 0\\.09044601986912117\ \(0\)\
\-\ buffer\\:\\ 0\\.08859399033538261\ \(0\)\
\-\ attendant\\:\\ 0\\.08859399033538261\ \(0\)\
\-\ variceal\\:\\ 0\\.08859399033538261\ \(0\)\
\-\ arcades\\:\\ 0\\.08859399033538261\ \(0\)\
\-\ hepatic\\:\\ 0\\.08823286451181395\ \(0\)\
\-\ formation\\:\\ 0\\.08783847247449791\ \(0\)\
\-\ occurs\\:\\ 0\\.08735648395841583\ \(0\)\
\-\ weightloss\\:\\ 0\\.08465628745620332\ \(0\)\
\-\ midepigastric\\:\\ 0\\.08186244280143846\ \(0\)\
\-\ hyperbilirubinemia\\:\\ 0\\.07792473992225916\ \(0\)\
\-\ obstruction\\:\\ 0\\.07760678732211669\ \(0\)\
\-\ is\\:\\ 0\\.07585604559005513\ \(0\)\
\-\ elevated\\:\\ 0\\.0755315588655986\ \(0\)\
\-\ replace\\:\\ 0\\.07513089526749431\ \(0\)\
\-\ esp\\:\\ 0\\.07513089526749431\ \(0\)\
\-\ flow\\:\\ 0\\.07379841001916705\ \(0\)\
\-\ expand\\:\\ 0\\.07296382099424795\ \(0\)\
\-\ hypercoagulability\\:\\ 0\\.07296382099424795\ \(0\)\
\-\ maintaining\\:\\ 0\\.07203820948804045\ \(0\)\
\-\ such\\:\\ 0\\.07127005907247755\ \(0\)\
\-\ obliterated\\:\\ 0\\.07119319238831501\ \(0\)\
\-\ hypercoagulable\\:\\ 0\\.07119319238831501\ \(0\)\
\-\ inherited\\:\\ 0\\.06969614723289977\ \(0\)\
\-\ compensatory\\:\\ 0\\.06839934773355016\ \(0\)\
\-\ collaterals\\:\\ 0\\.0672554895091357\ \(0\)\
\-\ lb\\:\\ 0\\.06673041189183208\ \(0\)\
\-\ thrombosed\\:\\ 0\\.06575844435372047\ \(0\)\
\-\ secondary\\:\\ 0\\.06567197471828472\ \(0\)\
\-\ coagulation\\:\\ 0\\.06446164485437085\ \(0\)\
\-\ lfts\\:\\ 0\\.06406519918705743\ \(0\)\
\-\ asian\\:\\ 0\\.06331778662995641\ \(0\)\
\-\ responsible\\:\\ 0\\.06331778662995641\ \(0\)\
\-\ manifestation\\:\\ 0\\.06296459969895561\ \(0\)\
\-\ circulation\\:\\ 0\\.05999886435788793\ \(0\)\
\-\ amylase\\:\\ 0\\.05879837874128379\ \(0\)\
\-\ lipase\\:\\ 0\\.05835686770194518\ \(0\)\
\-\ tumor\\:\\ 0\\.05795308181720676\ \(0\)\
\-\ average\\:\\ 0\\.0577300973204267\ \(0\)\
\-\ most\\:\\ 0\\.05766193721514838\ \(0\)\
\-\ affect\\:\\ 0\\.05733365165311328\ \(0\)\
\-\ and\\:\\ 0\\.057236933543518734\ \(0\)\
\-\ ascites\\:\\ 0\\.05714133704709623\ \(0\)\
\-\ state\\:\\ 0\\.05589226034768404\ \(0\)\
\-\ may\\:\\ 0\\.05575637322143914\ \(0\)\
\-\ rapidly\\:\\ 0\\.05540249757018481\ \(0\)\
\-\ pancreatitis\\:\\ 0\\.05493625266566185\ \(0\)\
\-\ unless\\:\\ 0\\.054491370138615464\ \(0\)\
\-\ with\\:\\ 0\\.05423842823087088\ \(0\)\
\-\ hypodense\\:\\ 0\\.0537923944412474\ \(0\)\
\-\ 51\\:\\ 0\\.05289133811941057\ \(0\)\
\-\ abd\\:\\ 0\\.05151800890768225\ \(0\)\
\-\ thrombus\\:\\ 0\\.05151800890768225\ \(0\)\
\-\ rapid\\:\\ 0\\.05151800890768225\ \(0\)\
\-\ response\\:\\ 0\\.05110024255069741\ \(0\)\
\-\ frequent\\:\\ 0\\.05079830413041692\ \(0\)\
\-\ spread\\:\\ 0\\.04976518336859517\ \(0\)\
\-\ invasion\\:\\ 0\\.04941517899382302\ \(0\)\
\-\ rarely\\:\\ 0\\.04941517899382302\ \(0\)\
\-\ leading\\:\\ 0\\.04924479619825293\ \(0\)\
\-\ veins\\:\\ 0\\.04916071281373989\ \(0\)\
\-\ rather\\:\\ 0\\.04907735118391819\ \(0\)\
\-\ disorders\\:\\ 0\\.04891274435773684\ \(0\)\
\-\ though\\:\\ 0\\.04812912832816033\ \(0\)\
\-\ ischemia\\:\\ 0\\.04797971660814126\ \(0\)\
\-\ mesenteric\\:\\ 0\\.04783256878934923\ \(0\)\
\-\ partially\\:\\ 0\\.047544797505417354\ \(0\)\
\-\ idiopathic\\:\\ 0\\.046860601251237616\ \(0\)\
\-\ development\\:\\ 0\\.045797826816774044\ \(0\)\
\-\ arterial\\:\\ 0\\.045621781447950205\ \(0\)\
\-\ extends\\:\\ 0\\.045621781447950205\ \(0\)\
\-\ children\\:\\ 0\\.04539191106558517\ \(0\)\
\-\ total\\:\\ 0\\.04539191106558517\ \(0\)\
\-\ described\\:\\ 0\\.04494787622939121\ \(0\)\
\-\ be\\:\\ 0\\.04494577576261647\ \(0\)\
\-\ function\\:\\ 0\\.04483996878317062\ \(0\)\
\-\ metastases\\:\\ 0\\.0447864613737381\ \(0\)\
\-\ mildly\\:\\ 0\\.044733247157061354\ \(0\)\
\-\ inflammation\\:\\ 0\\.044523259078933355\ \(0\)\
\-\ infarction\\:\\ 0\\.043489661874388484\ \(0\)\
\-\ nausea\\:\\ 0\\.04255556494147712\ \(0\)\
\-\ complications\\:\\ 0\\.04242916527979574\ \(0\)\
\-\ hypertension\\:\\ 0\\.042387395020801466\ \(0\)\
\-\ are\\:\\ 0\\.042042293664244834\ \(0\)\
\-\ subsequent\\:\\ 0\\.041939402502296504\ \(0\)\
\-\ in\\:\\ 0\\.04134391999386914\ \(0\)\
\-\ its\\:\\ 0\\.04099210530733568\ \(0\)\
\-\ compression\\:\\ 0\\.04056826043339318\ \(0\)\
\-\ early\\:\\ 0\\.039932853706045664\ \(0\)\
\-\ peripheral\\:\\ 0\\.039614413038387954\ \(0\)\
\-\ they\\:\\ 0\\.03958313581249729\ \(0\)\
\-\ risk\\:\\ 0\\.03958313581249729\ \(0\)\
\-\ extension\\:\\ 0\\.039215461482725\ \(0\)\
\-\ quadrant\\:\\ 0\\.038803393661058345\ \(0\)\
\-\ or\\:\\ 0\\.038544185306502145\ \(0\)\
\-\ labs\\:\\ 0\\.03838047181831967\ \(0\)\
\-\ does\\:\\ 0\\.0382980534715102\ \(0\)\
\-\ this\\:\\ 0\\.0380717278382747\ \(0\)\
\-\ 12\\:\\ 0\\.037869925956300746\ \(0\)\
\-\ neoplasm\\:\\ 0\\.03781771308728119\ \(0\)\
\-\ less\\:\\ 0\\.0376883959935294\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.037090572191547856\ \(0\)\
\-\ cancer\\:\\ 0\\.036899205009583526\ \(0\)\
\-\ adjacent\\:\\ 0\\.03590920716646511\ \(0\)\
\-\ 20\\:\\ 0\\.03573956843848999\ \(0\)\
\-\ bowel\\:\\ 0\\.03555220114294402\ \(0\)\
\-\ approximately\\:\\ 0\\.035348169053568475\ \(0\)\
\-\ days\\:\\ 0\\.03506953932065886\ \(0\)\
\-\ tenderness\\:\\ 0\\.034741610063829385\ \(0\)\
\-\ artery\\:\\ 0\\.034406052183704766\ \(0\)\
\-\ primary\\:\\ 0\\.0340639967439379\ \(0\)\
\-\ for\\:\\ 0\\.033581617473964084\ \(0\)\
\-\ when\\:\\ 0\\.03346379702261858\ \(0\)\
\-\ infection\\:\\ 0\\.03346379702261858\ \(0\)\
\-\ syndrome\\:\\ 0\\.033397506183349315\ \(0\)\
\-\ weeks\\:\\ 0\\.033201306172101513\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03313677722874506\ \(0\)\
\-\ likely\\:\\ 0\\.03310467283506267\ \(0\)\
\-\ time\\:\\ 0\\.03283598735914236\ \(0\)\
\-\ been\\:\\ 0\\.03227569466589401\ \(0\)\
\-\ blood\\:\\ 0\\.03217323555168902\ \(0\)\
\-\ due\\:\\ 0\\.031843998251185314\ \(0\)\
\-\ therapy\\:\\ 0\\.03182993370094329\ \(0\)\
\-\ lesions\\:\\ 0\\.03181588948989888\ \(0\)\
\-\ evidence\\:\\ 0\\.03144417523372666\ \(0\)\
\-\ common\\:\\ 0\\.03141719863236745\ \(0\)\
\-\ abdominal\\:\\ 0\\.030298816341729103\ \(0\)\
\-\ acute\\:\\ 0\\.0299683786740964\ \(0\)\
\-\ increased\\:\\ 0\\.02995678276794888\ \(0\)\
\-\ upper\\:\\ 0\\.02960400973812423\ \(0\)\
\-\ woman\\:\\ 0\\.028851631530783493\ \(0\)\
\-\ other\\:\\ 0\\.02876924231770877\ \(0\)\
\-\ small\\:\\ 0\\.028576324489837136\ \(0\)\
\-\ case\\:\\ 0\\.0278315187157996\ \(0\)\
\-\ have\\:\\ 0\\.027674504649760612\ \(0\)\
\-\ after\\:\\ 0\\.026874638149027085\ \(0\)\
\-\ well\\:\\ 0\\.026824144602463535\ \(0\)\
\-\ has\\:\\ 0\\.025304343090252562\ \(0\)\
\-\ disease\\:\\ 0\\.02325425100176408\ \(0\)\
\-\ from\\:\\ 0\\.022001868133535104\ \(0\)\
\-\ not\\:\\ 0\\.021869942998078068\ \(0\)\
\-\ an\\:\\ 0\\.02118413553356785\ \(0\)\
\-\ ct\\:\\ 0\\.02109066445354882\ \(0\)\
\-\ pain\\:\\ 0\\.01982356129789968\ \(0\)\
\-\ right\\:\\ 0\\.01836683863305498\ \(0\)\
\-\ patient\\:\\ 0\\.01801829577406726\ \(0\)\
\-\ year\\:\\ 0\\.01707267468582559\ \(0\)\
\-\ old\\:\\ 0\\.016395677551397377\ \(0\)\
